Khadija Saeed

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

Danaher (DHR) Stock on December 1, 2025: Q3 Beat, Legal Probes and Fresh Price Targets – Is the Premium Still Worth Paying?

Danaher (DHR) Stock on December 1, 2025: Q3 Beat, Legal Probes and Fresh Price Targets – Is the Premium Still Worth Paying?

Danaher Corporation (NYSE: DHR) enters December 2025 trading around the mid‑$220s per share, a high‑quality life‑sciences and diagnostics name that continues to command a premium valuation — and attract both bullish analysts and governance‑focused law firms.TS2+1 Below is a detailed,
1 429 430 431 432 433 456
Go toTop